Skip to content
Back to meeting Original
Dr. José Ramón Hernández García· @ramonphysician · X·· 2 days agoScore70

788RO

Body

🧬 #ESMO2026 788RO · ECLYPse: enco+cetux beyond progression + FOLFIRI en mCRC BRAF V600E (fase II, n=25). Cumplió primario: SLP 6m 66.7%, mediana 7.1 m, DCR 80% (ORR 15%). OS 12m 83.7%. Señal de control de enfermedad; un solo brazo → genera hipótesis. #CáncerColorrectal #BRAF

10 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
788ROmatched by Rapid oral: Gastrointestinal tumours, lower digestive

Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial

https://esmocongress.esmo.org

Source: Dr. José Ramón Hernández García · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.